Shweta Kurian, MD
Hematology & Oncology · Baltimore, MDNPI 1962645911
Payments from drug & device makers
What this record shows
3 manufacturers reported payments, led by AbbVie at 42.1% of the total. That places this record below the midpoint for hematology & oncology clinicians in MD, where the typical reported total is $2,111.
Across 3 payments — averaging $18.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$24
- Mirati Therapeutics, Inc.$21
- Gilead$12
Across 25 payments — averaging $26,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$391K
- Amgen$149K
- Pfizer$56K
- Novartis$52K
- Eli Lilly$9K
What the payments were for
- Food & beverage$2442%
- Education$3358%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Gilead | 1 | $12 |
How this compares
$57 in reported general payments places this provider in the 5th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 38 | $577,420 |
| LenvimaLenvatinib Mesylate | 21 | $488,538 |
| IbrancePalbociclib | 29 | $457,089 |
| ImbruvicaIbrutinib | 24 | $349,268 |
| CabometyxCabozantinib S-Malate | 11 | $242,145 |
| TalzennaTalazoparib Tosylate | 11 | $190,499 |
| LynparzaOlaparib | 12 | $171,907 |
| Everolimus | 11 | $89,323 |
| Exemestane | 80 | $16,465 |
| Anastrozole | 350 | $7,658 |
| EliquisApixaban | 11 | $6,057 |
| Letrozole | 116 | $3,384 |
| Prochlorperazine Maleate | 45 | $1,493 |
| Oxycodone Hcl | 47 | $968 |
| Hydroxyurea | 21 | $805 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baltimore
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Huzefa BahrainBaltimore$102K
- Tania JainBaltimore$95K
- Josephine FelicianoBaltimore$72K
- Abhijeet KumarBaltimore$66K
- Michael AuerbachBaltimore$64K
- Suman RaoBaltimore$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.